Johnson & Johnson could announce a deal as soon as Monday to buy Texas-based biotech firm Ollin Biosciences for up to $3.4 billion, the Financial Times reported, citing people familiar with the matter.
Discussions point to a potential agreement where the firm would disburse $2.2 billion in cash immediately to Ollin’s investors, alongside an additional $2.2 billion—wait, let’s keep exact numbers—$1.2 billion tied to future milestone achievements.
Clinical Implications for Retinal Disease Management
The deal centers on Ollin’s experimental drug candidate, OLN324. The therapy is currently in late-stage clinical development for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which the Financial Times described as two leading causes of vision loss.
Reflecting its broader strategy within the pharma sector, this step succeeds other recent buyout efforts by Johnson & Johnson. Earlier this year, the enterprise purchased Firefly Bio for $1 billion in cash to broaden its oncology portfolio, alongside its 2025 purchase of drugmaker Intra-Cellular Therapies for $14.6 billion aimed at strengthening its standing in neurological care.
Ollin Advances Late-Stage Studies for OLN324
- Clinical Status: OLN324 is currently in late-stage studies for DME and wet AMD.
- Funding: Ollin raised $330 million in June to advance the late-stage studies of the experimental eye disease drug.
- Strategic Growth: Johnson & Johnson has recently acquired smaller biotech and drugmaker companies, including Firefly Bio and Intra-Cellular Therapies.
Status of the Reported Deal
Reuters could not immediately verify the Financial Times report. Neither Johnson & Johnson nor Ollin Biosciences immediately responded to Reuters’ requests for comment outside business hours, so the financial terms of the potential deal remain unconfirmed by the companies.
| Acquisition Target | Focus Area | Investment Value |
|---|---|---|
| Ollin Biosciences | Eye disease (DME/AMD) | Up to $3.4 Billion |
| Firefly Bio | Cancer drug pipeline | $1.0 Billion |
| Intra-Cellular Therapies | Neurological disorder treatments | $14.6 Billion |
OLN324 Remains an Experimental Drug
OLN324 is an experimental drug and is not yet available for clinical use.
The exact timeline for the completion of the potential acquisition, which the Financial Times reported could be announced as soon as Monday, remains an open question.